Primary immunodeficiency diseases: an experimental model for molecular medicine
- 1 June 2001
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 357 (9271), 1863-1869
- https://doi.org/10.1016/s0140-6736(00)04959-x
Abstract
Primary immunodeficiency diseases represent a vast array of inherited disorders of the immune system. Major advances in the understanding of genetic basis and molecular mechanisms have occurred within the past 10 years, as a result of the tools of modern genetics. About three quarters of 100 primary immunodeficiency diseases can now be reliably diagnosed with molecular probes. In many cases, gene identification has enabled significant insight into the physiopathology of the related conditions. Therapeutic progress based on protein engineering and possibly gene therapy will also ensue.This publication has 58 references indexed in Scilit:
- X-linked immunodeficiency with hyper-IgM (XHIM)Clinical and Experimental Immunology, 2000
- A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patientsNature Genetics, 1998
- Natural and Engineered Disorders of Lymphocyte DevelopmentScience, 1998
- Mutation of RFXAP, a Regulator of MHC Class II Genes, in Primary MHC Class II DeficiencyNew England Journal of Medicine, 1997
- A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 KinaseScience, 1995
- A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome).Genes & Development, 1995
- Isolation of a novel gene mutated in Wiskott-Aldrich syndromeCell, 1994
- Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITAScience, 1994
- Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemiaCell, 1993
- The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinasesNature, 1993